{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:28:32Z","timestamp":1789738112094,"version":"4.0.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T00:00:00Z","timestamp":1363219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0058721","type":"journal-article","created":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T20:07:01Z","timestamp":1363291621000},"page":"e58721","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":66,"title":["RASopathic Skin Eruptions during Vemurafenib Therapy"],"prefix":"10.1371","volume":"8","author":[{"given":"Jeannine D.","family":"Rinderknecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone M.","family":"Goldinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Rozati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jivko","family":"Kamarashev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Kerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Belloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,3,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/1078-0432.CCR-09-1766","article-title":"Mitogen-activated protein\/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders","volume":"16(3)","author":"K Schad","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6(7)","author":"C Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1078-0432.CCR-11-1344","article-title":"Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1","volume":"18(1)","author":"JP Arnault","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6(10)","author":"ME Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","article-title":"Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management","volume":"148(3)","author":"L Zimmer","year":"2012","journal-title":"Arch Dermatol"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Zimmer L, Vaubel J, Livingstone E, Schadendorf D. Side effects of systemic oncological therapies in dermatology. J Dtsch Dermatol Ges (in press).","DOI":"10.1111\/j.1610-0387.2012.07942.x"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467(7315)","author":"G Bollag","year":"2010","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastasis, and other solid tumors: a phase 1 dose-escalation trial","volume":"379(9829)","author":"GS Falchook","year":"2012","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363(9)","author":"K Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/464358a","article-title":"Drug discovery: inhibitors that activate","volume":"464(7287)","author":"K Cichowski","year":"2010","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30(3)","author":"PA Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CCO.0b013e3283436e8c","article-title":"RAF inhibition and induction of cutaneous squamous cell carcinoma","volume":"23(2)","author":"C Robert","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364(26)","author":"PB Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ejca.2011.06.052","article-title":"New drugs in melanoma: It&apos;s a whole new world","volume":"47(14)","author":"AM Eggermont","year":"2011","journal-title":"Eur J Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464(7287)","author":"G Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"ref16","unstructured":"Dummer R, Rinderknecht J, Goldinger SM, Wagner I, Mitchell L, <etal>et al<\/etal>.. (2011) An Open-label Pilot Study of Vemurafenib in previously treated metastastic melanoma patients with brain metastasis. ASCO Meeting Abstracts J Clin Oncol 2011, Vol 29, abstract 8548."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1113752","article-title":"Ultraviolet A and photosensitivity during vemurafenib therapy","volume":"366(5)","author":"R Dummer","year":"2012","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, et al. Atypical melanocytic proliferations and new primary melanomas in advanced melanoma patients undergoing selective BRAF inhibition. J Clin Oncol (in press).","DOI":"10.1200\/JCO.2011.41.1660"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Dalle S, Poulalhon N, Thomas L. (2011) Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 365(15): 1448\u20139; author reply 1450.","DOI":"10.1056\/NEJMc1108651"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366(3)","author":"F Su","year":"2012","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140(2)","author":"SJ Heidorn","year":"2010","journal-title":"Cell"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Nazarian R, Shi H, Wang Q, Kong X, Koya RC, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468(7326): 973\u20137.","DOI":"10.1038\/nature09626"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1056\/NEJMe1111636","article-title":"RAF around the edges-the paradox of BRAF inhibitors","volume":"366(3)","author":"AT Weeraratna","year":"2012","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2133.2011.10744.x","article-title":"Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development","volume":"166(3)","author":"DH Siegel","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref25","first-page":"521","article-title":"Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome","volume":"164(3)","author":"DH Siegel","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/sj.jid.5700772","article-title":"FGFR3 mutations in epidermal nevi and seborrheic keratoses: lessons from urothelium and skin","volume":"127(7)","author":"C Hafner","year":"2007","journal-title":"J Invest Dermatol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaad.2012.06.045","article-title":"Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma","volume":"67(6)","author":"KP Boyd","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1200\/JCO.2011.39.8594","article-title":"Systemic retinoid therapy for chemoprevention of nonmelanoma skin sancer in a patient treated with vemurafenib","volume":"30(19)","author":"R Anforth","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/bjd.12080","article-title":"How cutaneous eruptions help to understand the mode of action of kinase inhibitors","volume":"167(5)","author":"R Dummer","year":"2012","journal-title":"Br J Dermatol"}],"updated-by":[{"DOI":"10.1371\/annotation\/d884b668-04f7-4ae6-96a3-a199df5b43be","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2013,10,9]],"date-time":"2013-10-09T00:00:00Z","timestamp":1381276800000}}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0058721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T13:38:35Z","timestamp":1589031515000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0058721"}},"subtitle":[],"editor":[{"given":"Keiran","family":"Smalley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,14]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0058721","relation":{"correction":[{"id-type":"doi","id":"10.1371\/annotation\/d884b668-04f7-4ae6-96a3-a199df5b43be","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,14]]}}}